Manganese neurotoxicity: new perspectives from behavioral, neuroimaging, and neuropathological studies in humans and non-human primates by Tomás R. Guilarte
REVIEW ARTICLE
doi: 10.3389/fnagi.2013.00023
Manganese neurotoxicity: new perspectives from
behavioral, neuroimaging, and neuropathological studies
in humans and non-human primates
Tomás R. Guilarte*
Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York, NY, USA
Edited by:
Anthony R. White, The University of
Melbourne, Australia
Reviewed by:
Dominic J. Hare, University of
Technology, Sydney, Australia
Ulrike Dydak, Purdue University,
USA
*Correspondence:
Tomás R. Guilarte, Department of
Environmental Health Sciences,
Mailman School of Public Health,
Columbia University, 722 West
168th St., Room 1105-E, New York,
NY 10032, USA
e-mail: trguilarte@columbia.edu
Manganese (Mn) is an essential metal and has important physiological functions for
human health. However, exposure to excess levels of Mn in occupational settings or from
environmental sources has been associated with a neurological syndrome comprising
cognitive deficits, neuropsychological abnormalities and parkinsonism. Historically, studies
on the effects of Mn in humans and experimental animals have been concerned with
effects on the basal ganglia and the dopaminergic system as it relates to movement
abnormalities. However, emerging studies are beginning to provide significant evidence
of Mn effects on cortical structures and cognitive function at lower levels than previously
recognized. This review advances new knowledge of putative mechanisms by which
exposure to excess levels of Mn alters neurobiological systems and produces neurological
deficits not only in the basal ganglia but also in the cerebral cortex. The emerging evidence
suggests that working memory is significantly affected by chronic Mn exposure and
this may be mediated by alterations in brain structures associated with the working
memory network including the caudate nucleus in the striatum, frontal cortex and parietal
cortex. Dysregulation of the dopaminergic system may play an important role in both the
movement abnormalities as well as the neuropsychiatric and cognitive function deficits
that have been described in humans and non-human primates exposed to Mn.
Keywords: manganese, neurotoxicity, Parkinson’s disease, dopamine, motor function, cognitive function, working
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INTRODUCTION
Manganese (Mn) is an essential trace metal that is required for
a number of enzymes important for normal cellular functions
(Aschner and Aschner, 2005). However, excess accumulation of
Mn in the brain results in a neurological syndrome with cognitive,
psychiatric and motor abnormalities (Pal et al., 1999; Olanow,
2004; Perl and Olanow, 2007; Guilarte, 2010). Following excess
exposure to Mn, the highest concentrations of Mn in the brain
occur in the basal ganglia, specifically in the globus pallidus,
caudate/putamen, and substantia nigra (Dorman et al., 2006;
Guilarte et al., 2006a). These same studies have shown that Mn
also accumulates in other brain structures within the cerebral
cortex and in white matter (Dorman et al., 2006; Guilarte et al.,
2006a). The accumulation of Mn in the basal ganglia is likely to
be responsible for a form of parkinsonism with overlapping, but
distinct clinical features with those seen in idiopathic Parkinson’s
disease (PD) (see below). Recently, there has been a great deal of
debate in the scientific literature regarding the possibility that Mn
may have an etiological role in idiopathic PD or accelerate the
expression of PD (Racette et al., 2001, 2005). From a different
perspective during the last decade there is mounting experimental
evidence that exposure to Mn, at lower doses than those needed
to produce motor function deficits, has a significant effect on
executive function and cognition (Klos et al., 2006; Schneider
et al., 2006, 2009; Roels et al., 2013). In this review, I examine the
available evidence from human and non-human primate studies
on the impact of elevated Mn exposures and its effects on motor
function and cognitive domains.
MANGANESE-INDUCED PARKINSONISM
The first description of Mn-induced parkinsonism goes back to
1837 when Couper provided the sequelae of workers employed
in the grinding of Mn oxide ore (Couper, 1837). In more mod-
ern times, there has been a number of reports describing clinical
expression of parkinsonism in occupationally exposed workers
(Mena et al., 1967; Cook et al., 1974; Huang, 2007; also see stud-
ies in Perl and Olanow, 2007 and in Guilarte, 2010) with clear
evidence that excess exposures to Mn produces motor function
deficits in humans and non-human primates that resemble some
aspects to those expressed in idiopathic PD (Perl and Olanow,
2007; Guilarte, 2010) as well as more subtle effects on motor
function, specifically fine motor control depending upon the level
of exposure (Perl and Olanow, 2007; Guilarte, 2010). However,
there are clear differences between Mn-induced parkinsonism
and idiopathic PD from a clinical perspective and in the underly-
ing neuropathology (Perl and Olanow, 2007; Guilarte, 2010) (see
next section).
The most compelling human evidence of Mn-induced parkin-
sonism in the last decade comes from a very unfortunate human
experiment in which young drug users inject very high levels
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of Mn from use of home-made psychostimulant preparations
(ephedron, also called methcathinone) (de Bie et al., 2007; Meral
et al., 2007; Sanotsky et al., 2007; Sikk et al., 2007, 2010, 2013;
Selikhova et al., 2008; Stepens et al., 2008, 2010; Varlibas et al.,
2008; Colosimo and Guidi, 2009; Yildirim et al., 2009; Iqbal et al.,
2012). These cases of young drug users with clinical parkinson-
ism as a result of drug abuse are reminiscent of young addicts
injecting 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
and expressing clinical parkinsonism in the early 1980s (Langston
et al., 1983). The ephedron home-made preparations is the result
of using potassium permanganate to oxidize ephedrine or pseu-
doephedrine and it is injected with minimal purification; thus,
users inject very high doses of Mn. These ephedron users exhib-
ited clinical parkinsonism that is not responsive to L-dopa therapy
(Sanotsky et al., 2007; Selikhova et al., 2008; Stepens et al., 2008;
Colosimo and Guidi, 2009; Sikk et al., 2013). This clinical obser-
vation suggests that the underlying neurobiology associated with
Mn-induced parkinsonism is different from the well-recognized
loss of dopamine neurons in the substantia nigra pars compacta
(SNpc) that is responsive to L-dopa therapy in idiopathic PD
patients (Savitt et al., 2006) and in MPTP subjects (Forno et al.,
1993; Forno, 1996) and MPTP exposed non-human primates
(Nerastet et al., 1994).
The etiological role of Mn in producing the motor function
deficits in these relatively young ephedron users can be con-
firmed by the extremely high levels of Mn measured in their
blood (Selikhova et al., 2008; Stepens et al., 2008; Sikk et al.,
2010, 2013) and the bilateral hyperintensive signal in the basal
ganglia observed in T1-weighted magnetic resonance imaging
(MRI) consistent with excess accumulation of Mn in the brain
(Selikhova et al., 2008; Stepens et al., 2008; Sikk et al., 2010, 2013).
Importantly, in Eastern European countries in which there is
expression of Mn-induced parkinsonism in ephedron drug users,
the synthesis of the ephedron uses potassium permanganate to
oxidize ephedrin or pseudoephedrin. On the other hand, in the
United States drug users make the same ephedrone preparation,
however, they oxidize the ephedrine with chromate and there is
no evidence of parkinsonism (Stepens et al., 2008). This provides
compelling evidence that the culprit in the home-made ephedron
preparations used in Eastern European countries is the high levels
of Mn that are injected by these individuals.
MANGANESE-INDUCED PARKINSONISM: DEGENERATION
OR DYSFUNCTION OF DOPAMINERGIC NEURONS?
HUMAN STUDIES
In the last decade there has been a great deal of debate in the
scientific literature about the potential role of Mn on the eti-
ology of idiopathic PD. Epidemiological studies indicate that
long-term exposure (>20 years) to Mn is associated with idio-
pathic PD (Gorell et al., 1999). Studies in welders have suggested
that Mn exposure precipitates an earlier expression of idiopathic
PD (Racette et al., 2001, 2005). However, the studies in welders
have been criticized from several perspectives (see Ravina et al.,
2001; Guilarte, 2010) and a confounding problem in human stud-
ies is that workers occupationally exposed to Mn could have
an underlying susceptibility to develop PD. Thus, it is difficult
to know whether the Mn exposure is the etiological agent that
induces idiopathic PD or whether there is a coincidental Mn
exposure in individuals that are destined to express the disease.
In an effort to examine the potential role of Mn in idiopathic
PD, a recent study used [18F]-Fluoro-L-Dopa Positron Emission
Tomography ([18F]-FDOPA PET) imaging on 20 asymptomatic
welders (exposed to welding fumes containing Mn), 20 subjects
with idiopathic PD and 20 normal controls (Criswell et al., 2011).
[18F]-FDOPA PET is a non-invasive neuroimaging method to
assess presynaptic dopamine terminal activity in vivo and has
been used in idiopathic PD patients as a marker of dopamine
terminal integrity (Gallagher et al., 2011; Jaimini et al., 2013).
Notably, [18F]-FDOPA uptake is dramatically decreased with a
distinct regional pattern in the caudate and putamen of idio-
pathic PD patients (Morrish et al., 1996; Nurmi et al., 2001; Hilker
et al., 2005; Gallagher et al., 2011). An important aspect of the
investigation by Criswell and colleagues is that welders were rel-
atively young (mean age 45.2 years), apparently asymptomatic
and in good health, thus reducing the possibility of expressing
an underlying idiopathic PD etiology in order to minimize the
likelihood of coincidental Mn exposure with idiopathic PD. The
authors found that welders expressed significantly elevated levels
of blood Mn and a higher pallidal index (the pallidal index is a
measure of Mn accumulation on the globus pallidus as a ratio
of the signal intensity in the globus pallidus over the intensity
in the frontal white matter using T1-weighted MRI) than con-
trols and subjects with idiopathic PD; thus confirming that the
welders were actively exposed to Mn. Upon neurological exam-
ination, welders demonstrated a slightly elevated average United
Parkinson’s Disease Rating Scale-subscale 3 (UPDRS3) score rel-
ative to controls indicative of subtle effects of Mn on motor
function while the idiopathic PD subjects had a much higher
score consistent with their diagnosis. The results of the [18F]-
FDOPA-PET studies indicated that the welders had a small (10%)
but significantly lower level of [18F]-FDOPA uptake in the cau-
date nucleus relative to controls but no effect on the anterior or
posterior putamen (Criswell et al., 2011). On the other hand,
idiopathic PD patients expressed the expected pattern of [18F]-
FDOPA uptake deficits in the caudate and putamen relative to
controls. That is, idiopathic PD subjects had marked reductions
in [18F]-FDOPA uptake in the putamen (∼52% in the posterior
putamen and 35% in the anterior putamen) with a smaller reduc-
tion in the caudate nucleus (∼17%) (Criswell et al., 2011). This
study showed that the pattern of the impairment in dopamine
terminal function in welders actively exposed to Mn-containing
welding fumes is not the same to that observed in idiopathic PD.
It should also be noted that the interpretation of the decrease
in [18F]-FDOPA uptake in the caudate in the welders exposed
to Mn should not necessarily be interpreted as representative
of dopamine terminal degeneration as is the case in idiopathic
PD. It is possible that Mn exposure could alter enzymes that
are responsible for [18F]-FDOPA metabolism and this possibility
needs to be ruled out. Other types of PET studies should also be
performed that would be more representative of dopamine ter-
minal integrity and are less likely to be influenced by changes
in dopamine metabolizing enzymes and/or changes in dopamine
levels. For example, [11C]-dihydrotetrabenazine (DTBZ) PET
for vesicular monoamine trasnporter type-2 (VMAT-2) is more
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likely to represent structural changes in dopamine terminals than
[18F]-FDOPA PET when it relates to studies with Mn.
The findings of Criswell et al. (2011) do suggests that the small
but significant Mn-induced decrease in [18F]-FDOPA uptake in
the caudate nucleus may be associated with potential effects
on cognitive domains since the caudate nucleus has extensive
connections to cortical structures, especially to frontal corti-
cal areas that are involved in executive function (see below).
Consistent with this hypothesis, several studies in early idiopathic
PD patients show that reductions in [18F]-FDOPA uptake in the
caudate nucleus are associated with deficits in working memory
performance and executive function (Rinne et al., 2000; Jokinen
et al., 2009, 2013), effects that were not associated with reduction
in [18F]-FDOPA uptake in the putamen.
This recent study using state-of-the-art PET instrumentation
and analysis provides evidence of a relative lack of dopamine neu-
ron terminal degeneration in welders expressing small increases
on the UPDRS3 scale. Previous studies in smelter workers with
clinical parkinsonism have reported normal [18F]-FDOPA-PET
in the striatum (Huang, 2007). Further, neuroimaging stud-
ies performed in the ephedrone users indicating normal levels
of dopamine terminals, based on dopamine transporter (DAT)
levels, in the striatum using SPECT imaging despite the fact
that they express clinical parkinsonism (Selikhova et al., 2008;
Colosimo and Guidi, 2009; Sikk et al., 2010, 2013; Iqbal et al.,
2012). Thus, the most recent human studies with state-of-the-
art neuroimaging methodologies indicate that there is a relative
lack of dopamine neuron terminal degeneration in the caudate
and putamen as a result of Mn exposure. These findings raise
the important question, what is the underlying neurobiological
deficit in dopaminergic neurons in Mn-induced parkinsonism?
NON-HUMAN PRIMATE STUDIES
During the last decade, our laboratory in collaboration with a
multidisciplinary group of investigators has been studying the
neurological consequences of chronic exposures to moderate lev-
els of Mn (Guilarte et al., 2006a,b, 2008a,b; Burton and Guilarte,
2009; Burton et al., 2009; Verina et al., 2011, 2013; Schneider
et al., 2006, 2009). These on-going studies use research naïve
Cynamolgos macaques (5–6 years of age at the initiation of the
study) in which there is extensive behavioral and neuroimaging
assessment prior to (baseline) and at two different time points
after initiation of Mn administration (Guilarte et al., 2006b,
2008a). After the animals have gone through the behavioral
and neuroimaging protocols [the latter includes T1-weighted
MRI (MRI), Magnetic Resonance Spectroscopy (MRS), PET and
currently Diffusion Tensor Imaging (DTI)] ex vivo neurochem-
ical and neuropathological confirmation of the PET findings as
well as other neurochemical and neuropathological outcomes
are performed. One of the neuroimaging studies performed is
to assess DAT levels as a putative synaptic marker of dopamine
terminal integrity in the caudate and putamen using [11C]-
methylphenidate PET. Another PET study uses a continuous infu-
sion of [11C]-raclopride (a D2-dopamine receptor ligand) with
amphetamine challenge in order to measure both D2-dopamine
receptor (D2R) levels and in vivo dopamine release (Laruelle,
2000; Zhou et al., 2006). Importantly, the imaging studies provide
an internal control since each animal receives a “baseline” (prior
to Mn exposure) imaging set (MRI/MRS/DTI/PET). In addition,
to theMn-exposed animals, an “imaged-control” group was used.
This group of animals goes through the same imaging protocol,
but they do not receive Mn. A second “naïve controls” group was
also used for the neuropathological endpoints and this group of
animals does not receive Mn exposure nor does it go through the
imaging protocol.
The results of our PET studies demonstrate that chronic expo-
sure to moderate levels of Mn does not produce the loss of
dopamine terminals, i.e., there was a lack of dopamine termi-
nal degeneration in the caudate and putamen based on [11C]-
methylphenidate PET for DAT under our experimental Mn dose
and exposure conditions (Guilarte et al., 2006b, 2008a). On
the other hand, we found a highly significant effect of Mn on
dopamine terminal dysfunction since there was a marked (∼60%
from baseline) and progressive decrease of in vivo dopamine
release in the striatum of Mn-exposed animals measured by PET
(Guilarte et al., 2006b, 2008a). This effect was not observed in
the “imaged-control” group. Therefore, the impairment of in vivo
dopamine release was the direct result of the Mn administration
(Guilarte et al., 2008a).
One potential explanation for the impairment of in vivo
dopamine release measured by PET in the Mn-exposed animals
is that Mn produces a decrease in the synthesis of dopamine,
thus resulting in lower levels of synaptic (vesicular) dopamine
available for release. To answer this questions, a number of
ex vivo neurochemical studies were performed in the caudate
and putamen of the same animals in which PET studies were
performed. The results show that when all control groups were
combined (imaged-controls and naïve controls) and used as a ref-
erent group, there were no significant differences on the levels of
dopamine and metabolites in the caudate and there was only an
effect of Mn on dopamine levels in the putamen when compared
to the naïve controls only (Guilarte et al., 2008a). A similar effect
was observed for DAT and vesicular dopamine transporter-2
(VMAT-2) in the caudate and putamen. Lastly, there was no
effect of Mn-exposure on DAT or tyrosine hydroxylase (TH)
immunostaining in the caudate and putamen. In summary, the
non-human primate studies performed under highly controlled
experimental and Mn dosing conditions indicate that exposure
to moderate levels of Mn does not result in dopamine neu-
ron degeneration as in idiopathic PD but it produces significant
dopamine neuron dysfunction. We have proposed that the sub-
tle fine motor control deficits observed in these animals is the
result of a dopamine release deficit (Guilarte et al., 2006b, 2008a;
Guilarte, 2010). Our non-human primate findings are consistent
with the most recent neuroimaging studies in humans indicating
a lack of dopamine neuron terminal degeneration in subjects with
clinical parkinsonism resulting from ephedrone use (Selikhova
et al., 2008; Colosimo and Guidi, 2009; Sikk et al., 2010; Iqbal
et al., 2012).
While the current review does not include rodent studies, there
is recent evidence in the literature that rodents exposed to Mn
also have impairment in dopamine release with no change in
total tissue dopamine levels, dopamine neuron terminals in the
striatum, or TH-positive dopaminergic cell bodies in the SNpc
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(Vidal et al., 2005; Peneder et al., 2011). Combined these studies
provide evidence that Mn-induced parkinsonism may be the
result of the inability of dopamine neuron terminals to release
dopamine rather than a decrease of dopamine synthesis in intact
terminals and/or the loss of dopamine as a result of terminal
degeneration. These findings provide a logical explanation to
the evidence that Mn-induced parkinsonism is not responsive to
L-dopa therapy (Lu et al., 1994; Sanotsky et al., 2007; Selikhova
et al., 2008; Stepens et al., 2008; Colosimo and Guidi, 2009; Sikk
et al., 2013) as is idiopathic PD since in Mn-induced parkinson-
ism there is no apparent loss of dopamine terminal or dopamine
levels in the striatum. Our findings in non-human primates that
Mn impairs dopamine release needs to be confirmed in humans
exposed to Mn. Collectively, our PET findings implicate a novel
mechanism by which dopamine neuron dysfunction, that is, the
inability to release dopamine, rather than a degenerative process
can result in clinical parkinsonism as a result of Mn exposure.
EFFECTS OF MANGANESE EXPOSURE ON
NEUROPSYCHIATRIC SYMPTOMS AND COGNITIVE
FUNCTION
The clinical expression of Mn-induced neurotoxicity in humans
has been described as a continuum with different stages with
distinct clinical manifestations (Mergler et al., 1999). Humans
exposed to Mn express changes in sleep patterns and mood with
uncontrollable laughter and crying, euphoria, aggressiveness, hal-
lucinations and psychosis (Donaldson, 1987). An acute effect
of Mn intoxication has been described as a clinical condition
with symptoms reminiscent of schizophrenia and amphetamine-
induced psychosis (Donaldson, 1987; Perl and Olanow, 2007).
Although the current knowledge on the psychiatric aspects of
chronic Mn exposure are limited, recent studies indicate that
humans with increased exposure to Mn (Bowler et al., 2003, 2006,
2007a,b; Josephs et al., 2005; Park et al., 2009) and from medical
conditions that results in increased Mn accumulation in the brain
(Mirowitz et al., 1991; Klos et al., 2006) express impairments
in attention and learning and memory function suggestive of
frontal lobe and subcortical dysfunction. Studies have shown that
workers occupationally exposed to Mn have a higher incidence
of neuropsychiatric symptoms than referents (Bouchard et al.,
2007) and elevated levels of Mn markedly increase neuropsy-
chiatric symptoms associated with alcohol abuse (Sassine et al.,
2002). An increasing number of reports also indicate effects on
working memory (Bowler et al., 2003, 2006, 2007a,b; Klos et al.,
2006) and poor cognitive performance (Mergler and Baldwin,
1997; Santos-Burgoa et al., 2001; Bowler et al., 2003, 2007a,b;
Klos et al., 2006). Importantly, the effects of Mn on work-
ing memory points to deficits in frontal lobe function, a brain
region known to be involved in neuropsychiatric illnesses such as
schizophrenia (Goldman-Rakic, 1999; Abi-Dargham et al., 2002).
A growing number of reports in children with elevated exposures
to Mn indicate below average performance in verbal and visual
memory tests (Woolf et al., 2002; Wright et al., 2006) and intel-
lectual function (Wasserman et al., 2006; Claus Henn et al., 2010;
Bouchard et al., 2011; Menezes-Filho et al., 2011; Khan et al.,
2012). Children followed from birth through the early years have
cord blood Mn concentrations that were negatively correlated
with scores on attention, non-verbal memory and hand skills
(Takser et al., 2003). Despite these studies, basic knowledge on
mechanism(s) by which Mn produces psychiatric symptoms and
cognitive impairment is lacking. Therefore, a great deal can be
learned not only from Mn effects on basal ganglia function but
also from effects on cognitive domains associated with the frontal
cortex and other cortical and subcortical structures.
THE CEREBRAL CORTEX—A NOVEL TARGET OF
MANGANESE NEUROTOXICITY
There is a paucity of knowledge on the neuropathological con-
sequences of excess Mn accumulation in cortical regions and
specifically in the frontal cortex. This is based in part on the
fact that: (1) most studies on Mn-induced neurochemical and
neuropathological changes have been focused on basal ganglia
structures due to its association with movement abnormalities
and parkinsonism, and (2) Mn accumulates to a high degree in
the basal ganglia. Besides the suggestion from neuropsychological
and cognitive tests of frontal cortex involvement in Mn-induced
neurological dysfunction, a review of the literature brings to light
a lack of neuropathological studies in which Mn effects on the
cerebral cortex have been performed. It is only recently when neu-
roimaging studies have interrogated cortical regions to examine
their susceptibility to Mn-induced neurotoxicity. In this context,
our recent studies in non-human primates have reported pro-
ton MRS metabolite changes in Mn-exposed animals (Guilarte
et al., 2006a). This includes a decrease in N-acetylaspartate (NAA)
to creatine (Cr) ratio (NAA/Cr) in the parietal cortex with a
nearly significant decrease (p = 0.055) in frontal white matter
(Guilarte et al., 2006a). A decrease in the NAA/Cr ratio is rep-
resentative of neuronal dysfunction and/or neuronal loss (Clark,
1998; Block et al., 2002). Since this original publication, two
human studies have described effects of Mn on brain metabo-
lites in the cerebral cortex. Chang et al. (2009) have shown that
cognitive decline in welders was associated with a decrease in
myoinositol/creatine (mI/tCr) ratio in the anterior cingulate cor-
tex indicative of glial involvement. More recently, another MRS
study in smelters showed a small but significant decrease in
NAA/tCr ratio in the frontal cortex that was strongly correlated
with cumulative Mn exposure (Dydak et al., 2011). Therefore,
there is emerging evidence that exposure to Mn results in altered
levels of brain metabolites in the cerebral cortex that reflect neu-
ronal loss or dysfunction and glial cell activation. The only other
evidence describing cortical involvement with brain Mn accu-
mulation is a case report of an individual exhibiting progressive
dementia, and extrapyramidal syndrome with an elevated Mn
body burden (Banta and Markesbery, 1977). Brain biopsy and
examination of cortical tissue revealed numerous neuritic plaques
and neurofibrillary tangles in the right frontal lobe typical of
Alzheimer’s disease (AD) (Banta and Markesbery, 1977).
NEUROPATHOLOGICAL CHANGES IN THE FRONTAL CORTEX
OF MN-EXPOSED NON-HUMAN PRIMATES
Previous reports from our on-going studies on the neurologi-
cal effects of Mn in non-human primates have provided com-
pelling evidence of Mn-induced pathology in the frontal cortex
of young, research naïve animals (Guilarte et al., 2008b; Verina
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et al., 2013). Using microarray technology in frontal cortex tis-
sue from Mn-exposed and control animals, we found significant
alterations in genes with biological functions associated with:
(1) cholesterol metabolism and transport, (2) axonal/vesicular
transport, (3) inflammation and the immune response, (4) cell
cycle regulation and DNA repair, (5) and proteasome function
and protein folding and turnover. The most highly upregulated
gene was β-amyloid precursor-like protein 1 (APLP1), a mem-
ber of the amyloid precursor protein (APP) family associated
with AD (Guilarte et al., 2008b). The increase in APLP1 gene
expression was confirmed at the protein level using immuno-
histochemistry. We also found diffused β-amyloid plaques (6E10
antibody immunohistochemistry) in the frontal cortex fromMn-
exposed animals that were not observed in age-matched controls.
These findings were unexpected as these were young adoles-
cent animals and normally non-human primates do not express
β-amyloid diffuse plaques at an early age, although there is evi-
dence of diffused β-amyloid plaques in aged (>20 years of age)
non-diseased monkeys (Kimura et al., 2003, 2005). Examination
of frontal lobe tissue also provided evidence of cortical and sub-
jacent white matter degeneration based on silver staining. In
the gray matter, histological staining provided evidence of neu-
rons with a significant degree of intracytoplasmic vacuolization.
In some of the animals, we observed neurons with hypertropic
nuclei, a condition that has been associated with the early stages
of AD (Iacono et al., 2008, 2009). Histological assessment of the
frontal cortex also showed cells with apoptotic stigmata and astro-
cytosis in both the gray and white matter. More recently, we have
reported evidence of α-synuclein aggregation in the frontal cor-
tex gray and white matter from the same Mn-exposed animals
(Verina et al., 2013). As noted earlier, these Mn-exposed ani-
mals expressed a near significant (p = 0.05) decrease in NAA/Cr
ratio in the frontal cortex white matter (Guilarte et al., 2006a)
consistent with the observation of white matter degeneration in
post-mortem brain tissue. Therefore, our studies provided the
first evidence of significant pathology in the frontal and parietal
cortex of non-human primates exposed to Mn.
Recent human studies also support neurodegenerative changes
resulting from Mn exposure in frontal cortex white matter.
Stepens et al. (2010) report that individuals injecting ephedron-
containing Mn express white matter abnormalities based on DTI.
The authors describe evidence of diffuse white matter changes
reflected by reductions in fractional anisotropy (FA) in the
ephedron users. They also find effects specific to white matter
underlying the right ventral premotor cortex and the medial pre-
frontal cortex. The authors indicate that the clinical features of
these ephedron users point to a disorder of higher-level motor
programming and that the pattern of motor function deficits
resemble executive function deficits similar to those displayed
by patients with prefrontal cortex lesions (Stepens et al., 2010).
Another human study examining white matter ultrastructural
integrity in welders also reveal white matter changes measured
by DTI (Kim et al., 2011). They show that FA was significantly
reduced in the corpus callosum and frontal white matter of
welders. The FA values in these white matter regions was sig-
nificantly associated with blood Mn levels and pallidal index.
Importantly, the degree of FA disruption was associated with
impaired attention, lower working memory and deficits in execu-
tive function tests (Kim et al., 2011).
These findings provided strong evidence that the frontal cor-
tex gray matter and subjacent white matter are vulnerable, but
previously unrecognized targets for Mn-induced neurotoxicity
despite the fact that Mn accumulates in cortical structures at sig-
nificantly lower concentrations than in the basal ganglia. These
observations suggest that the neurotoxicological effects of Mn
are not solely based on the degree to which Mn accumulates in
different brain regions but they are also based on the vulnerabil-
ity of a specific brain region to Mn-induced neurotoxicity. The
emerging evidence in humans and non-human primates suggest
that future studies on subjects with environmental and occupa-
tional exposures to Mn or in patients with medical conditions in
which excess brain Mn accumulation occurs should be tested for
neuropsychiatric symptoms and cognitive function deficits.
EFFECTS OF MANGANESE EXPOSURE ONWORKING
MEMORY
In the previous section evidence is provided that exposure to
elevated levels of Mn results in detrimental effects on corti-
cal structures, specifically the frontal and parietal cortex. Recent
human and non-human primates studies suggest that a result-
ing effect of Mn-induced neuropathology in the frontal cortex is
working memory deficits. Chang et al. (2010) report that welders
with chronic Mn exposure express increased brain activity mea-
sured by functional MRI in workingmemory networks during the
2-back verbal working memory task. They interpret these find-
ings as the welders requiring more neural resources in working
memory networks to compensate for subtle deficits in working
memory. In another study, Wasserman et al. (2011) found sig-
nificant associations between Mn levels in drinking water and
reductions in Perceptual Reasoning andWorking Memory scores.
Our non-human primate studies were the first to provide ini-
tial evidence of Mn effects on working memory under highly
controlled experimental conditions (Schneider et al., 2006, 2009).
We showed that chronic Mn exposure resulted in deficits in
non-spatial and spatial working memory. Non-spatial working
memory assessed by delayed matching to sample performance
appeared to be more affected than spatial working memory using
a variable delayed response task (Schneider et al., 2009). In
general, the human and non-human primate studies provide sub-
stantial evidence for impairments of cognitive domains that are
mediated by the frontal cortex. Further, the non-human primate
findings also implicate brain metabolite changes in the parietal
cortex, a brain region that is important for working memory
performance and plays an important role in integrating sen-
sory information and visuo-spatial processing (Constantinidis
and Wang, 2004; Seger, 2006; Linden, 2007).
CAN DOPAMINE NEURON DYSFUNCTION IN THE STRIATUM
AND/OR FRONTAL CORTEX EXPLAIN THE WORKING
MEMORY DEFICITS OBSERVED IN Mn EXPOSED
NON-HUMAN PRIMATES?
Working memory is closely associated with frontal cortex
function (Constantinidis and Wang, 2004; Linden, 2007) and
dopamine neurotransmission in the striatum (Rinne et al., 2000;
Frontiers in Aging Neuroscience www.frontiersin.org June 2013 | Volume 5 | Article 23 | 5
Guilarte New perspectives in manganese neurotoxicity
Sawamoto et al., 2008; Jokinen et al., 2009) and the frontal cor-
tex (Brozoski et al., 1979; Rotaru et al., 2007). The dopamine cell
bodies located in the SNpc project to the caudate and putamen
and this nigrostriatal system is involved in motor control. In addi-
tion, there are direct mesolimbic dopaminergic projections from
the ventral tegmental area to the frontal cortex (Bjorklund and
Dunnett, 2007). The caudate nucleus receives dopaminergic input
from the SNpc and it can influence frontal cortex function via
well-defined frontostriatal circuits (Alexander et al., 1986; Seger,
2006). Human and non-human primates studies show that the
dorsolateral prefrontal cortex (DLPFC) is an important region for
the execution of working memory tasks with reciprocal connec-
tions to other cortical structures such as the parietal, temporal
and cingulate cortex and these combined participate in a corti-
cal network related to working memory (Kubota and Niki, 1971;
Petrides et al., 1993; Berman et al., 1995; Cohen et al., 1997).
Lesions or dysfunction of the caudate nucleus has been
reported to produce impairment in the delayed response tasks
that assesses working memory (Levy et al., 1997; White,
2009). Relevant to our own studies, Mn-exposed animals have
impairments of both spatial and non-spatial working memory
(Schneider et al., 2009) and they also express a significant impair-
ment of in vivo dopamine release in the striatum (Guilarte et al.,
2008a). Further, welders exposed to Mn express an early deficit
in dopamine neuron function specific to the caudate nucleus
and not the putamen (Criswell et al., 2011). These findings
suggest that dopamine neuron dysfunction via impairment of
dopamine release in the striatum and specifically in the caudate
may be associated with the working memory deficits expressed in
Mn-exposed non-human primates and in humans. Other stud-
ies have shown that the levels of NAA in the DLPFC predict
the activation of cortical regions involved in the execution of
working memory tasks such as the frontal, parietal and tempo-
ral cortices and this network has been found to be affected in
mental disorders such as schizophrenia (Bertolino et al., 2000;
Castner et al., 2004). Postmortem studies in the frontal cor-
tex of Mn-exposed non-human primates have found a signifi-
cant degree of neuronal degeneration with diffused β-amyloid
plaques and α-synuclein aggregation (Guilarte et al., 2008b;
Verina et al., 2013) implicating a potentially important role of
this neuropathology in the working memory deficits observed
in Mn-exposed non-human primates (Schneider et al., 2009).
Imaging studies in welders exposed to Mn support a Mn-induced
neuronal cell death or dysfunction in the frontal cortex based
on decreased NAA/tCr ratio (Dydak et al., 2011), an effect that
was associated with cumulative Mn exposure. Combined these
studies provide evidence that several brain regions (i.e., the cau-
date nucleus, the frontal cortex and the parietal cortex) within
the working memory network appear to have substantial neu-
ropathology and/or dysfunction as a result of chronic exposure
to Mn.
Experimental animal and human studies have shown that
dopamine is a key neurotransmitter in the regulation of work-
ing memory in the frontal cortex and caudate nucleus (Levy
et al., 1997; Aalto et al., 2005; Cools et al., 2008; Landau
et al., 2009; Backman et al., 2011; Cools and D’Esposito,
2011). Microdialysis studies have shown that working memory
tasks induce the release of dopamine in the prefrontal cortex
of monkeys (Watanabe et al., 1997) and rats (Phillips et al.,
2004) and there is increased blood flow to prefrontal and
parietal cortex in humans performing working memory tasks
(Bertolino et al., 2000; Cabeza and Nyberg, 2000). Other stud-
ies have shown that D1-dopamine receptor (D1R) antagonists
can impair working memory (Sawaguchi and Goldman-Rakic,
1991) while low doses of D1R agonists can improve work-
ing memory (Arnsten et al., 1994). Contrary to using low
doses of dopamine receptor agonists, high doses of D1R ago-
nists also impair working memory performance, an effect that
is abrogated by pretreatment with a D1R antagonist (Zahrt
et al., 1997; Goldman-Rakic et al., 2000). These findings sug-
gest that either low levels or excessive levels of D1R dopamine
receptor stimulation can have a negative impact on working
memory performance (Goldman-Rakic et al., 2000; Cools and
D’Esposito, 2011). Based on this literature, it is likely that
the impairment of in vivo dopamine release measured in the
striatum of Mn-exposed animals may be responsible for their
impairment in working memory (see Guilarte et al., 2008a;
Schneider et al., 2009). Alternatively, it is possible that chronic
Mn exposure may also alter in vivo dopamine release in the
frontal cortex, and along with deficits of dopamine release in
the caudate nucleus may precipitate deficits on working mem-
ory performance.
ANALYSIS OF In vivo DOPAMINE RELEASE IN THE FRONTAL
CORTEX: PET IMAGINGWITH [11C]-FLB 457
While the displacement of D2R specific PET ligands such as
[11C]-raclopride by an acute amphetamine challenge has been
validated and used extensively to measure in vivo dopamine
release in the striatum (Laruelle, 2000). The use of this method-
ology is just emerging for the cerebral cortex (Narendran et al.,
2009, 2011a,b, 2013). Since dopamine innervation to cortical
structures is significantly lower than to the striatum, that is,
dopamine terminals and dopamine receptor levels are much
lower in the frontal cortex than in the caudate/putamen, in vivo
dopamine release PET in cortical structures is a much more dif-
ficult task to perform. However, the development and use of
high affinity D2R-PET ligands such as [11C]-FLB 457 (Kd =
0.06 nM) and [18F]-fallypride (Kd = 0.14nM) have made such
studies possible. Several publications have now described the reli-
ability of using [11C]-FLB 457 to measure in vivo dopamine
release in the cerebral cortex of humans and non-human pri-
mates (Narendran et al., 2009, 2011a,b, 2013). Further, a recent
study has shown that the degree of [11C]-FLB 457 binding poten-
tial reduction measured by PET was directly associated with the
amount of extracellular dopamine release induced by the acute
amphetamine administration (Narendran et al., 2013). In sum-
mary, the ability to measure in vivo dopamine release in the
cerebral cortex using PET is an extremely valuable approach to
understand the molecular basis of the working memory impair-
ments observed in humans and non-human primates exposed
to Mn. We are currently performing these types of studies in
our Mn-exposed animals in order to make associations between
in vivo dopamine in cortical regions and working memory per-
formance.
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SUMMARY
In the last decade there has been significant progress using
state-of-the-art neuroimaging and behavioral methodologies that
have opened up a new understanding of Mn neurotoxicol-
ogy. While historically the focus of Mn neurotoxicity has been
associated with parkinsonism as a result of the high levels of
exposure that occurred in the mining and processing of Mn
ore and in other occupational settings, the last decade has
brought about compelling experimental evidence that at lower
cumulative doses of Mn that are likely to occur from occu-
pational and environmental exposures, other non-motor neu-
rological effects appear to be more prevalent and these seem
to be associated with cognitive function deficits. The later may
be the result of Mn producing brain chemistry and structural
changes in cortical regions, and the frontal and parietal cortex
appear to be sensitive targets. Lastly, because of its relevance
to motor and cognitive domains, it is possible that dysfunction
of the dopaminergic system could be a common mechanism
by which Mn could have an impact on both cognitive and
motor function deficits observed in humans and non-human
primates.
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